Market Insights Health OTC Pharmaceuticals

Digestives & Intestinal Remedies - Finland

Finland

In Finland, the Digestives & Intestinal Remedies market market generates a revenue of US$54.81m in 2024.
It is projected to experience an annual growth rate of 1.79% (CAGR 2024-2029).
Comparatively, in China generates the highest revenue in this market, amounting to US$4,408.00m in 2024.
When considering the population size, in Finland generates a per person revenue of US$9.88 in 2024.
In Finland, the demand for natural and herbal digestive remedies is on the rise, as consumers prioritize holistic approaches to gut health.

Key regions: Canada, United States, Australia, Brazil, Japan

Market

Region

Region comparison

Currency

Analyst Opinion

The Digestives & Intestinal Remedies market in Finland is developing steadily, driven by changing customer preferences and the local special circumstances of the country.

Customer preferences: In Finland, there is an increasing demand for natural and herbal remedies in the Digestives & Intestinal Remedies market. Customers are becoming more health-conscious and are seeking products that are gentle on their digestive system. They are also looking for remedies that provide long-term relief rather than just temporary solutions. As a result, there is a growing trend towards products that contain natural ingredients such as herbs and plant extracts.

Trends in the market: One of the key trends in the Digestives & Intestinal Remedies market in Finland is the rising popularity of probiotics. Probiotics are live bacteria and yeasts that are beneficial for the digestive system. They help restore the natural balance of bacteria in the gut and improve digestion. Probiotic supplements and foods have gained significant traction among Finnish consumers, who are increasingly aware of the role of gut health in overall well-being. This trend is expected to continue driving the growth of the market in the coming years.Another trend in the market is the increasing availability of over-the-counter (OTC) remedies. Previously, many Digestives & Intestinal Remedies required a prescription in Finland. However, there has been a shift towards making certain products available without a prescription, making it more convenient for consumers to access these remedies. This has led to increased sales and a wider range of options for customers.

Local special circumstances: Finland has a high prevalence of gastrointestinal disorders, such as irritable bowel syndrome (IBS) and gastroesophageal reflux disease (GERD). These conditions affect a significant portion of the population and contribute to the demand for Digestives & Intestinal Remedies. The cold climate and dietary habits in Finland may also play a role in the prevalence of digestive issues, as certain foods can trigger symptoms. As a result, there is a greater need for effective remedies to manage these conditions, driving the growth of the market.

Underlying macroeconomic factors: Finland has a strong healthcare system and high healthcare expenditure per capita. This provides a favorable environment for the development and availability of Digestives & Intestinal Remedies. The government's focus on preventive healthcare and promoting a healthy lifestyle also contributes to the demand for these products. Additionally, the aging population in Finland is more likely to experience digestive issues, further driving the market growth.In conclusion, the Digestives & Intestinal Remedies market in Finland is experiencing steady growth due to changing customer preferences, including a preference for natural remedies, and the local special circumstances of the country, such as the high prevalence of gastrointestinal disorders. The availability of over-the-counter remedies and the underlying macroeconomic factors, such as a strong healthcare system and an aging population, also contribute to the market's development.

Methodology

Data coverage:

Data encompasses B2C spend. Figures are based on the OTC Pharmaceuticals market values, representing revenues generated by both product sales which take place exclusively in pharmacies and products which can be purchased elsewhere. Sales by hospitals are not included.

Modeling approach / Market size:

Market sizes are determined by a combined top-down and bottom-up approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use data from national statistical offices, international institutions, trade associations, and self-medication associations. Next, we use relevant key market indicators and data from country-specific associations, such as consumer healthcare spending, out-of-pocket healthcare expenditure, health system accessibilities, and GDP. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. Whereas this market covers only OTC drugs, the Statista Pharmaceuticals market covers both OTC and prescription drugs.